|
Glioblastoma / Treatment
|
|
Imatinib (Gleevec)
|
|
Home >
Database > Glioblastoma
> Treatment
>
Imatinib
|
|
|
Contents
|
|
|
|
Glioblastoma
|
|
|
|
|
Dresemann G, Weller M, Rosenthal MA, Wedding U,
Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O,
Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C,
Sieder C, Sorenson G, Parker R, Nikolova Z
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to
standard dose temozolomide
J Neurooncol. 2009 Aug 18;. [Epub ahead of print]
.JPG)
Abstract
|
|
G. Dresemann
Imatinib (STI 571)/ plus hydroxyurea: Safety and efficacy in pre-treated,
progressive Glioblastoma Multiforme (GBM) patients (pts): An update on the
initial 30 pts
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1516.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1516
|
|
G. Dresemann
Imatinib (STI571) plus hydroxyurea: Safety and
efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients
(pts)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1550
|
|
G.
Dresemann
STI 571/hydroxyurea in progressive, pretreated
glioblastoma (GB) patients (pts.)
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
465
|
|
Gregor
Dresemann
CD
117 (c-kit) - predictive for efficacy of imatinib in pretreated glioblastoma
patients?
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No. 2082
|
|
M. Holdhoff, K. A. Kreuzer, C.
Appelt, R. Scholz, A. Jordan, B. Hildebrandt, C. A. Schmidt, R. A. Van Etten, B.
Dörken, P. Le Coutre
Combined administration of imatinib mesylate and
ionizing radiation leads to increased radiosensitivity in the human glioblastoma
cell line RuSi RS1
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1564
|
|
Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger
E, CNOack PM, Stiles CD
Intracranial
inhibition of platelet-derived growth factor-mediated glioblastoma cell growth
by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
Cancer Res 2000 Sep 15;60(18):5143-50 (Full Text)
|
|
|
Pursche S, Schleyer E, von Bonin M, Ehninger G,
Said SM, Prondzinsky R, Illmer T, Wang Y, Hosius C, Nikolova Z, Bornhäuser
M, Dresemann G
Influence of enzyme-inducing antiepileptic drugs on trough level of
imatinib in glioblastoma patients
Curr Clin Pharmacol. 2008 Sep;3(3):198-203
Abstract | .png)
Reprint
|
|
E. Raymond, A.
Brandes, A. Van Oosterom, C. Dittrich, P. Fumoleau, B. Coudert,
C. Twelves, C. De Balincourt, D. Lacombe, M. Van Den Bent
Multicentre
phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1501
|
|
|
Reardon
DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P,
CNOomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J,
Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z
Multicentre phase II studies evaluating imatinib plus hydroxyurea in
patients with progressive glioblastoma
Br J Cancer. 2009 Nov 10;. [Epub ahead of print]
Abstract
|
|
Huan Ren, Alf Giese,
Tingchang Chou, Steven Pelech, Nikolai Rainov
Biological activity of a novel tyrosine
kinase inhibitor of the 2-phenylaminopyrimidine class, Imatinib
(STI571, Gleevec), on human glioblastoma cells
Proceedings of the AACR, Volume 44, 2nd ed., July 2003, Abstract
No. R3776
|
|
Patrick
Y Wen, W K Yung, Kenneth Hess, Sandra Silberman, Michael Hayes, David Schiff, Frank Lieberman, Timothy F
Cloughesy, Lisa M DeAngelis, Susan M Chang,
Larry Junck, Howard A Fine, Karen Fink, H I Robins, Jeffrey J Raizer, Lauren E
Abrey, Minesh P Mehta, Elizabeth A Maher, Peter M CNOack, John Kuhn, Renaud
Capdeville, Richard S Kaplan, Anthony Murgo, Charles Stiles, Michael D Prados
Phase I study of STI571 (Gleevec) for patients with
recurrent malignant gliomas and meningiomas (NABTC 99-08)
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No. 288
|
|
|
Glioma
|
|
|
|
|
Benny
O, Menon LG, Ariel G, Goren E, Kim SK, Stewman C, CNOack PM, Carroll RS,
Machluf M
Local delivery of poly lactic-co-glycolic acid microspheres containing
imatinib mesylate inhibits intracranial xenograft glioma growth
Clin Cancer Res. 2009 Feb 15;15(4):1222-31
Abstract
|
|
M. van den Bent, A.
Brandes, M. Frenay, P. Fumoleau, R.
Stupp, C. Dittrich, B. Coudert, P.
Clement, D. Lacombe and E. Raymond
Multicentre phase II study of imatinib mesylate in patients with recurrent
anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and
anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug
Development Group (NDDG) and Brain Tumor Group (BTG) study
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1517.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1517
|
|
H. S. Friedman, J.
Quinn, J. Rich, J. Vredenburgh, A.
Desjardins, S. Sathornsumetee, A. Salvado,
Z. Nikolova, D. Bigner and D. Reardon
Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of
recurrent malignant glioma: Phase II study results
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1515.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1515
|
|
A. Katz, C. H. Barrios, R.
Abramoff, S. D. Simon, J. Tabacof, R. C. Gansl
Imatinib (STI 571) is active in patients (PTS) with
high-grade gliomas progressing on standard therapy
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1542
|
|
Landonio Giuseppe,
Riva Maurizio, Galli Carlo, Schiavo Roberta, Carminati Ornella, Secondino Simona,
Gambacorta Marcello, Defanti Carlo Alberto, Siena Salvatore
Overexpression
of c-kit oncogene in human brain tumors
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
295
|
|
|
Raymond E, Brandes AA, Dittrich C, Fumoleau P,
Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC,
Gorlia T, Lacombe D, van den Bent MJ.
Phase II study of imatinib in patients with recurrent gliomas of various
histologies: a European Organisation for Research and Treatment of Cancer
Brain Tumor Group Study
J Clin Oncol. 2008 Oct 1;26(28):4659-65
Abstract
|
|
|
Reardon DA, Egorin MJ, Desjardins A, Vredenburgh
JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ,
Friedman HS
Phase I pharmacokinetic study of the vascular endothelial growth factor
receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and
hydroxyurea for malignant glioma
Cancer. 2009 Feb 26;. [Epub ahead of print]
Abstract
|
|
Reardon DA, Desjardins A, Vredenburgh JJ,
Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S,
McLendon R, Herndon JE 2nd, Friedman AH, Salvado AJ, Friedman HS.
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus
temozolomide: phase 1 trial in adults with malignant glioma.
Neuro Oncol.
2008 Jun;10(3):330-40. Epub 2008 Mar 21.
Abstract
|
Reprint
|
|
F.
S. Viola, F. Morrone, J. Stella, F. Spiller, A. Battastini, C. H. Barrios
Combination
of STI571 and temozolamide on inhibition of rat and human glioma cell lines
proliferation
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No. 469
|
|
|
Pediatric
Patients
|
|
|
|
|
Baruchel
S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C,
Halton J, Egorin MJ, Reis RM, Martinho O, Stempak D, Hawkins C, Gammon J,
Bouffet E
A
Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly
targeted study of imatinib in recurrent and refractory paediatric central
nervous system tumours
Eur
J Cancer. 2009 Jun 6. [Epub ahead of print]
Abstract
|
|
|
|
